Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation

Ayalew Tefferi, Shaji K Kumar, R. C. Wolf, Martha Lacy, D. J. Inwards, J. M. Gloor, R. C. Albright, Patrick Sequeira Kamath, Mark R Litzow

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT) results in considerable morbidity and mortality. No therapy has been shown to be uniformly effective. Several studies have highlighted the pivotal role of endothelial injury and the hemostatic system in the pathogenesis of HVOD. Charcoal hemofiltration has been shown to be effective for adsorbing circulating bilirubin and other protein-bound toxins and for supporting patients in hepatic failure. We describe two adult patients with severe, biopsy-proven HVOD (peak bilirubin levels, more than 50 mg/dl in both cases) after HSCT who were successfully treated with charcoal hemofiltration after other treatments failed (including defibrotide in one patient). Both patients were heavily treated before they underwent either autologous (melphalan and total body irradiation conditioning) or allogeneic (cyclophosphamide and total body irradiation conditioning) HSCT. Additional studies are warranted to confirm this preliminary observation and investigate the mechanism of action.

Original languageEnglish (US)
Pages (from-to)997-999
Number of pages3
JournalBone Marrow Transplantation
Volume28
Issue number10
DOIs
StatePublished - 2001

Fingerprint

Hepatic Veno-Occlusive Disease
Hemofiltration
Charcoal
Hematopoietic Stem Cell Transplantation
Whole-Body Irradiation
Bilirubin
Melphalan
Liver Failure
Hemostatics
Cyclophosphamide
Observation
Morbidity
Biopsy
Mortality
Wounds and Injuries
Therapeutics
Proteins

Keywords

  • Charcoal hemoperfusion treatment
  • Transplant-related complication

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. / Tefferi, Ayalew; Kumar, Shaji K; Wolf, R. C.; Lacy, Martha; Inwards, D. J.; Gloor, J. M.; Albright, R. C.; Kamath, Patrick Sequeira; Litzow, Mark R.

In: Bone Marrow Transplantation, Vol. 28, No. 10, 2001, p. 997-999.

Research output: Contribution to journalArticle

@article{022ad83f3d9149b1a62ac08368090844,
title = "Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation",
abstract = "Hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT) results in considerable morbidity and mortality. No therapy has been shown to be uniformly effective. Several studies have highlighted the pivotal role of endothelial injury and the hemostatic system in the pathogenesis of HVOD. Charcoal hemofiltration has been shown to be effective for adsorbing circulating bilirubin and other protein-bound toxins and for supporting patients in hepatic failure. We describe two adult patients with severe, biopsy-proven HVOD (peak bilirubin levels, more than 50 mg/dl in both cases) after HSCT who were successfully treated with charcoal hemofiltration after other treatments failed (including defibrotide in one patient). Both patients were heavily treated before they underwent either autologous (melphalan and total body irradiation conditioning) or allogeneic (cyclophosphamide and total body irradiation conditioning) HSCT. Additional studies are warranted to confirm this preliminary observation and investigate the mechanism of action.",
keywords = "Charcoal hemoperfusion treatment, Transplant-related complication",
author = "Ayalew Tefferi and Kumar, {Shaji K} and Wolf, {R. C.} and Martha Lacy and Inwards, {D. J.} and Gloor, {J. M.} and Albright, {R. C.} and Kamath, {Patrick Sequeira} and Litzow, {Mark R}",
year = "2001",
doi = "10.1038/sj.bmt.1703267",
language = "English (US)",
volume = "28",
pages = "997--999",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation

AU - Tefferi, Ayalew

AU - Kumar, Shaji K

AU - Wolf, R. C.

AU - Lacy, Martha

AU - Inwards, D. J.

AU - Gloor, J. M.

AU - Albright, R. C.

AU - Kamath, Patrick Sequeira

AU - Litzow, Mark R

PY - 2001

Y1 - 2001

N2 - Hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT) results in considerable morbidity and mortality. No therapy has been shown to be uniformly effective. Several studies have highlighted the pivotal role of endothelial injury and the hemostatic system in the pathogenesis of HVOD. Charcoal hemofiltration has been shown to be effective for adsorbing circulating bilirubin and other protein-bound toxins and for supporting patients in hepatic failure. We describe two adult patients with severe, biopsy-proven HVOD (peak bilirubin levels, more than 50 mg/dl in both cases) after HSCT who were successfully treated with charcoal hemofiltration after other treatments failed (including defibrotide in one patient). Both patients were heavily treated before they underwent either autologous (melphalan and total body irradiation conditioning) or allogeneic (cyclophosphamide and total body irradiation conditioning) HSCT. Additional studies are warranted to confirm this preliminary observation and investigate the mechanism of action.

AB - Hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT) results in considerable morbidity and mortality. No therapy has been shown to be uniformly effective. Several studies have highlighted the pivotal role of endothelial injury and the hemostatic system in the pathogenesis of HVOD. Charcoal hemofiltration has been shown to be effective for adsorbing circulating bilirubin and other protein-bound toxins and for supporting patients in hepatic failure. We describe two adult patients with severe, biopsy-proven HVOD (peak bilirubin levels, more than 50 mg/dl in both cases) after HSCT who were successfully treated with charcoal hemofiltration after other treatments failed (including defibrotide in one patient). Both patients were heavily treated before they underwent either autologous (melphalan and total body irradiation conditioning) or allogeneic (cyclophosphamide and total body irradiation conditioning) HSCT. Additional studies are warranted to confirm this preliminary observation and investigate the mechanism of action.

KW - Charcoal hemoperfusion treatment

KW - Transplant-related complication

UR - http://www.scopus.com/inward/record.url?scp=0035202855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035202855&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703267

DO - 10.1038/sj.bmt.1703267

M3 - Article

VL - 28

SP - 997

EP - 999

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -